The National Institute of Allergy and Infectious Diseases, part of the National Institutes of Health, launched a clinical trial to test a vaccine designed to protect against mosquito-transmitted diseases, such as Zika, malaria, and West Nile and dengue fevers.
The vaccine triggers an immune response to mosquito saliva. The study also will investigate whether mosquitoes that feed on study participants die early or reproduce less, which could slow disease transmission. The study is expected to enroll up to 60 healthy adults and conclude summer 2018.
For more information and updates about the Zika virus, visit America’s Essential Hospitals’ resource page.
Contact Director of Policy Erin O’Malley at email@example.com or 202.585.0127 with questions.